Imatinib in neurofibromatosis type 2.

Area of Science:

• Neurology
• Oncology
• Genetics

Background:

• Neurofibromatosis type 2 (NF-2) is a genetic disorder characterized by tumor development, often affecting cranial nerves.
• Hearing loss is a significant complication of NF-2, impacting patient quality of life.

Observation:

• A 30-year-old male with a decade-long history of NF-2 and pre-existing hearing impairment presented with rapidly worsening symptoms.
• The patient faced a high risk of complete hearing loss in his left ear due to disease progression.

Findings:

• Initial treatment with imatinib stabilized the NF-2 progression for four months before discontinuation due to adverse effects.
• Subsequent treatment with bevacizumab maintained stable disease for eight months, indicating potential therapeutic benefit.

Implications:

• This case highlights the challenges in managing progressive NF-2 and the potential utility of targeted therapies.
• Further research into the efficacy and tolerance of imatinib and bevacizumab in NF-2 is warranted.